(MedPage Today) — Over 60% of patients who started semaglutide (Wegovy) for obesity were still taking it a year later; but only one in seven stayed on the drug over 3 years, a pharmacy claims analysis from Prime Therapeutics found.
Even when…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/116327
Author :
Publish date : 2025-07-01 17:42:00
Copyright for syndicated content belongs to the linked Source.
